UBS Group’s ENDRA Life Sciences NDRA Stock Holding History

UBS Group’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362	Sell	68 -84	-55%	-$427	﹤0.01%	9896
2026 Q1	$707	Buy	152 +140	+1,167%	+$555	﹤0.01%	9780
2025 Q4	$54	Sell	12 -94	-89%	-$536	﹤0.01%	10262
2025 Q3	$570	Sell	106 -4,589	-98%	-$24K	﹤0.01%	9620
2025 Q2	$16.5K	Buy	+4,695	New	+$18.1K	﹤0.01%	8567
2025 Q1	–	Sell	-95	Closed	-$595	–	10555
2024 Q4	$595	Buy	+95	New	+$633	﹤0.01%	9416
2024 Q3	–	Sell	-32	Closed	-$5.38K	–	9878
2024 Q2	$5.38K	Buy	+32	New	+$13.8K	﹤0.01%	8003
2024 Q1	–	Hold	0	–	–	–	8867
2023 Q1	–	Sell	-1	Closed	-$8.75K	–	10092
2022 Q4	$8.75K	Buy	+1	New	+$8.38K	﹤0.01%	8734
2022 Q3	–	Sell	-1	Closed	-$9K	–	10718
2022 Q2	$9K	Hold	1	–	–	﹤0.01%	8155
2022 Q1	$11K	Hold	1	–	–	﹤0.01%	8306
2021 Q4	$19K	Hold	1	–	–	﹤0.01%	7907
2021 Q3	$49K	Hold	1	–	–	﹤0.01%	6351
2021 Q2	$64K	Hold	1	–	–	﹤0.01%	6213
2021 Q1	$79K	Buy	+1	New	+$74.9K	﹤0.01%	6140
2020 Q4	–	Hold	0	–	–	–	7837
2020 Q3	–	Hold	0	–	–	–	7128
2020 Q2	–	Hold	0	–	–	–	7780
2020 Q1	–	Hold	0	–	–	–	7621
2019 Q2	–	Hold	0	–	-$3K	–	8052
2019 Q1	–	Hold	0	–	–	–	7341
2018 Q2	–	Hold	0	–	-$6K	–	8159
2018 Q1	–	Hold	0	–	–	–	7153
2017 Q4	–	Hold	0	–	-$12K	–	8002
2017 Q3	–	Hold	0	–	–	–	6787
2017 Q2	–	Hold	0	–	–	–	6917

Other funds holding NDRA

ACM

Altium Capital Management New York $68.8M AUM 7.27% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

UBS Group's NDRA Position: Q2 2026 in Review

UBS Group reduced its ENDRA Life Sciences (NDRA) stake by 55% in Q2 2026, selling an estimated $427 and leaving 68 shares worth $362. The position accounts for ﹤0.01% of the portfolio, ranked #9896.

UBS Group first reported a position in NDRA in Q1 2021 and has held it in 14 quarters since. The position peaked at $79K in Q1 2021. 10 funds tracked by Wall St. Rank hold NDRA as of Q2 2026.

UBS Group held 68 shares of ENDRA Life Sciences worth $362 as of Q2 2026.
UBS Group sold 84 ENDRA Life Sciences shares in Q2 2026, an estimated $427.
ENDRA Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9896 holding.
UBS Group first reported a position in ENDRA Life Sciences in Q1 2021 and has held it in 14 quarters since.
UBS Group's ENDRA Life Sciences position peaked at $79K in Q1 2021.
10 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.